Tilray Stock Down 90% as Rescheduling Hopes Fade, International Drag Persists

Rescheduling Timeline Slippage Weighs on North American Cannabis Equities

The DEA's failure to finalize Schedule III rescheduling by Q2 2026 has eliminated the near-term catalyst that equity analysts had priced into Tilray and peer MSO valuations. The agency's Notice of Proposed Rulemaking, published in May 2024, triggered a public-comment period that closed in July 2024. No final rule has been published as of May 30, 2026. Administrative Law Judge hearings, originally forecast for late 2025, have been postponed twice—most recently in March 2026.

Tilray's equity decline mirrors the broader Nasdaq cannabis index, down 74 percent over the same 63-month period. Tilray's 90-percent drawdown significantly exceeds the sector average, though, reflecting company-specific headwinds in its international operations and U.S. beverage segment. The stock traded at $67 in February 2021; it closed at $1.42 on May 29, 2026.

For background on the DEA timeline and its impact on MSO equity performance, see the CannIntel topic hub on Tilray stock performance.

European Medical Cannabis Revenue Misses Forecasts for Fifth Consecutive Quarter

Tilray's German medical-cannabis sales grew just 8 percent year-over-year in Q3 FY2026, missing the company's 22-percent growth guidance and underperforming domestic competitors Aurora and Canopy Growth. According to Tilray's February 2026 earnings transcript, the company attributed the shortfall to pricing pressure from new BfArM cultivation licenses awarded to six German producers in 2025, which expanded domestic supply by an estimated 12 metric tons annually.

Key revenue metrics from Tilray's international cannabis segment:

• Germany Q3 FY2026 revenue: €11.2 million, down from €12.1 million in Q2
• Portugal cultivation facility operating at 62% capacity utilization
• Average wholesale price per gram in Germany: €4.80, down 19% year-over-year
• Patient count in Tilray's German pharmacy network: 8,400, up 11% but below the 14% sector growth rate

The company's Portugal facility, licensed for 95,000 square feet of canopy, has struggled to secure offtake agreements with other EU medical programs. Poland's medical cannabis program, which Tilray had targeted for export sales, remains restricted to domestic producers under a March 2025 Ministry of Health directive.

U.S. Beverage Segment Shows Growth but Can't Offset Cannabis Losses

Tilray's U.S. craft-beer and non-alcoholic beverage portfolio grew 14 percent in Q3 FY2026, but the segment's $89 million in quarterly revenue remains dwarfed by the company's $310 million in total quarterly losses, driven primarily by goodwill impairments on cannabis assets. SweetWater Brewing and Montauk Brewing posted double-digit volume growth in the Southeast and Mid-Atlantic, according to Nielsen off-premise data cited in the earnings call.

The beverage segment operates at a 6.2-percent EBITDA margin, though. Compare that to the 28-percent margin Tilray reported on its Canadian adult-use cannabis business in 2022. The company hasn't provided updated margin guidance for its German medical operations, citing "competitive dynamics" in its latest 10-Q filing.

Tilray CEO Irwin Simon stated in the February earnings call that the company would prioritize beverage M&A over cannabis expansion in 2026, a strategic pivot that equity analysts interpreted as a de-emphasis of the rescheduling thesis. The stock fell 11 percent in the session following that disclosure.

280E Liability and Institutional Ownership Both Decline

Tilray's exposure to Section 280E tax disallowance is minimal compared to U.S.-touching MSOs, because the company doesn't operate plant-touching businesses in states where cannabis remains federally illegal—but its institutional ownership has fallen to 22 percent, down from 48 percent in 2021. The company's primary tax burden stems from Canadian and European jurisdictions, where cannabis is federally legal and normal business-expense deductions apply.

Institutional selling accelerated in Q1 2026. Vanguard reduced its position by 38 percent; BlackRock trimmed its stake by 29 percent, according to 13F filings. Retail ownership now constitutes approximately 61 percent of the float, with the remainder held by insiders and strategic partners including Anheuser-Busch InBev, which holds a 4.1-percent stake acquired in 2023.

The math on a rescheduling-driven recovery is challenging. Even if Schedule III reclassification were finalized tomorrow, Tilray's U.S. beverage operations—its only domestic revenue stream—would see no direct tax benefit, because they already operate under normal tax treatment. The company's German and Portuguese cannabis businesses are unaffected by U.S. scheduling. A rescheduling win would benefit U.S. MSOs like Curaleaf and Trulieve, not Tilray's international model.

Analysts at Canaccord Genuity downgraded Tilray to "hold" in April 2026, cutting their 12-month price target from $3.50 to $1.80. The firm cited "structural headwinds in Germany, no near-term U.S. federal catalyst, and dilution risk from the company's $150 million at-the-market equity program."

Two signals to watch: BfArM's June 2026 decision on whether to expand the list of qualifying conditions for medical cannabis in Germany, which could broaden Tilray's addressable patient base, and whether the DEA schedules ALJ hearings before the U.S. midterm election cycle begins in earnest this fall.